KymaThera
KymaThera Raises $80M Series B for Selective PI3Kα Inhibitor
KymaThera announced $80M in Series B financing on October 6, 2026. KymaThera raised an $80 million Series B led by Alta Partners to advance K-1728, an oral PI3Kα inhibitor for cancer and vascular malformations.
Round details
The financing includes backing from Alta Partners, Venrock, Foresite Capital, J. Wood Capital. The company did not publish a valuation with the announcement.
- Round: Series B
- Capital announced: $80M
- Total funding reported: $100M+
How the company plans to use the capital
KymaThera said proceeds will primarily support the advancement of K-1728, and that the financing is expected to fund development through initial clinical proof-of-concept.
Why this matters for GTM teams
The financing follows a 2024 Series A co-led by Foresite Capital and Venrock, both of which participated in the Series B. KymaThera is initially developing K-1728, which is designed to inhibit disease-driving PI3Kα mutations while sparing wild-type PI3Kα, for HR+/HER2- breast cancer and PI3Kα-driven vascular malformations.
Fresh capital is often an operational signal rather than a buying signal by itself. Teams should validate the company’s hiring pattern, product launches, geographic expansion, and technology priorities before choosing the message and timing of outreach.
Source and methodology
This report is based on the company’s announcement and records the disclosed amount, round, investors, location, and stated use of funds. SalesTools Research does not estimate undisclosed valuation or revenue figures.
Primary source: KymaThera Series B announcement.
Company Info
Investors (4)
Share
Related Reports
Wabi Raises $55M at $1.25B Valuation in IVP-Led Funding
Wabi announced $55 million in funding led by IVP at a $1.25 billion valuation, which it said will support continued product development and expansion.
StimCardio Raises $30M Series A for Wearable AF Therapeutic
StimCardio announced the closing of an oversubscribed $30 million Series A led by Metis Medtech, expected to fund the company through its planned NeuroPulse 2 pivotal study and preparation for an FDA De Novo submission.
Casap Raises $56M Series B for AI Agents in Financial Services
Casap raised a $56 million Series B led by Base10 Partners, with Experian and Synchrony participating, to advance its AI agent platform for financial services.
Turn your sales ideas into reality today
Pick a plan and go live today. Change or cancel any time.
Get started


